Recruiting studies: Newly Diagnosed Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 · 29 location(s) · European Myeloma Network B.V. · NCT07107529 Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Thera
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06140966 FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethas
Phase 3 · 38 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT06187441 Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07296627 IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Phase 2 · 1 location(s) · Dickran Kazandjian, MD · NCT06376526 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Dar
Phase 3 · 270 location(s) · Janssen Research & Development, LLC · NCT05552222 Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Phase 1 · 1 location(s) · Susan Bal · NCT07333261 ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106710 Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Phase N/A · 13 location(s) · Shanghai Zhongshan Hospital · NCT07663253 A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Mye
Phase N/A · 5 location(s) · Bristol-Myers Squibb · NCT06698887 Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT06407947 Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3 · 69 location(s) · University of Heidelberg Medical Center · NCT06216158 Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Phase 2 · 29 location(s) · University Hospital, Lille · NCT05572229 Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05091372 Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in T
Phase 3 · 64 location(s) · Intergroupe Francophone du Myelome · NCT06918002 Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Phase 3 · 5 location(s) · University of Leeds · NCT07649525 Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
Phase N/A · 1 location(s) · FengYan Jin · NCT06099912 Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Phase 2/Phase 3 · 6 location(s) · University Hopsital Schleswig Holstein Campus Lübeck · NCT05665140 Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Dia
Phase N/A · 4 location(s) · Universiteit Antwerpen · NCT07087964 A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethas
Phase 1/Phase 2 · 2 location(s) · Hellenic Society of Hematology · NCT05573802 Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Phase N/A · 1 location(s) · All4Cure · NCT06149910 MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106736 Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
Phase 2 · 10 location(s) · PETHEMA Foundation · NCT07045909 Selinexor and Backbone Treatments of Multiple Myeloma Patients
Phase 1/Phase 2 · 25 location(s) · Karyopharm Therapeutics Inc · NCT02343042 Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Phase 2 · 5 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05145400 A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Parti
Phase 1/Phase 2 · 32 location(s) · Regeneron Pharmaceuticals · NCT05828511 A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
Phase N/A · 6 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06497738 Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
Phase N/A · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06682156 BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06793449 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · 649 location(s) · ECOG-ACRIN Cancer Research Group · NCT04566328

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.